Developing and Testing an Opioid Taper Intervention Before Total Knee Arthroplasty: Phase 2 Intervention Development
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Arthritis Knee
- Sponsor
- University of Alabama at Birmingham
- Enrollment
- 45
- Locations
- 1
- Primary Endpoint
- Acceptability
- Status
- Recruiting
- Last Updated
- 11 months ago
Overview
Brief Summary
The goal of this clinical trial is to develop an pharmacist-led preoperative opioid taper intervention for patients undergoing total knee or hip replacement who are on chronic opioids before their surgery. The main questions it aims to answer are:
- Is the intervention feasible and acceptable to patients?
- Does the intervention result in a decrease in opioid dose during the preoperative period?
Participants will meet with a clinical pharmacist, who will provide some basic education on pain and opioids, and will propose an opioid taper schedule. The pharmacist will then follow-up with the participant by phone each week until surgery to assess progress and adjust the taper as necessary.
Investigators
Kevin Riggs
Assistant Professor
University of Alabama at Birmingham
Eligibility Criteria
Inclusion Criteria
- •decided to pursue primary, unilateral total knee or hip arthroplasty with planned surgery date in 4-8 weeks
- •currently taking between 20 and 90 MME of oral opioids, and that dose has been stable for at least 3 months
- •have a reliable telephone number for contact
- •speaks English
Exclusion Criteria
- •Taking opioid medications that include:
- •Buprenorphine
- •Methadone
- •Long-acting formulations of opioid pain medications (e.g., extended-release oxycodone and extended-release morphine)
- •Transdermal formations of opioid pain medications (e.g., fentanyl patches)
Outcomes
Primary Outcomes
Acceptability
Time Frame: From enrollment until approximately 2 weeks after surgery
Mixed-methods assessment of the intervention by participants. Participants will provide qualitative feedback at multiple points during and after the intervention, and will quantitatively rate satisfaction at the end of the study. These results will be analyzed jointly to determine acceptability.
Secondary Outcomes
- Study Retention Rate(From enrollment until approximately 2 weeks after surgery)
- Perioperative Pain(From enrollment until approximately 2 weeks after surgery)
- Taper Efficacy(From enrollment until the time of surgery)
- Study Recruitment Rate(From enrollment until approximately 2 weeks after surgery)